Clinical Trial Update: Biomarkers Predicting Response in Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride

View source ↗

Summary

This clinical trial update examines biomarkers that may predict response in patients with non-small cell lung cancer who were previously treated with erlotinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Lung Cancer | Status: COMPLETED